NCT00398372

Brief Summary

To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2000

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2000

Completed
6 years until next milestone

First Submitted

Initial submission to the registry

November 9, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 10, 2006

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2007

Completed
2.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2009

Completed
Last Updated

June 2, 2011

Status Verified

July 1, 2010

Enrollment Period

6.6 years

First QC Date

November 9, 2006

Last Update Submit

May 31, 2011

Conditions

Lymphoma, Non-HodgkinLymphomas: Non-HodgkinLymphomas: Non-Hodgkin Cutaneous LymphomaLymphomas: Non-Hodgkin Diffuse Large B-CellLymphomas: Non-Hodgkin Follicular / Indolent B-CellLymphomas: Non-Hodgkin Mantle CellLymphomas: Non-Hodgkin Marginal ZoneLymphomas: Non-Hodgkin Peripheral T-CellLymphomas: Non-Hodgkin Waldenstr Macroglobulinemia

Outcome Measures

Primary Outcomes (1)

  • To characterize the molecular and cell biology of the tumor cells in lymphoma.

    6 months

Interventions

RituximabDRUG
EpratuzumabDRUG

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University School of Medicine

Stanford, California, 94305, United States

Location

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin

Interventions

Rituximabepratuzumab

Condition Hierarchy (Ancestors)

LymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Murine-DerivedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins

Study Officials

  • Wen-Kai Weng

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 9, 2006

First Posted

November 10, 2006

Study Start

November 1, 2000

Primary Completion

June 1, 2007

Study Completion

September 1, 2009

Last Updated

June 2, 2011

Record last verified: 2010-07

Locations

US(1)